Analysts advised investors to subscribe to Concord Biotech IPO given its complex product portfolio, presence in niche space, strong client relationship and high entry barriers. The company is one of the leading global manufacturers of select fermentation-based APIs (F-APIs) across immunosuppressants and oncology with a market share of over 20% by volume in 2022.
Sebi bars Vijay Mallya from accessing securities market for 3 years
According to the order, Mallya is prohibited from buying, selling, or dealing in securities directly or indirectly, and from being associated with the securities market